cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25934/00006399
title: 26 weeks treatment with 250 mg vs. 500 mg roflumilast vs. placebo in patients with chronic obstructive pulmonary disease (dose range finding trial).

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006400
title: 26 weeks treatment with 500 /mg roflumilast in patients with chronic obstructive pulmonary disease.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006401
title: Withdrawal of 500/mg roflumilast after 12 weeks of treatment versus continued treatment for 24 weeks versus placebo in patients with chronic obstructive pulmonary disease.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006404
title: A 24 Week, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Roflumilast (250 Mcg or 500 Mcg) Daily in Patients With Asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006405
title: A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Chronic Asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006406
title: Efficacy and safety of roflumilast 500 ?g once daily compared with placebo as an add-on therapy to fluticasone propionate 125 ?g twice daily over 24 weeks in patients with asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006407
title: The MOVE-study: Morning Versus Evening Administration of 500 Mcg Roflumilast Once Daily for 6 Weeks in Patients With Asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006408
title: A comparison of 500 ?g Roflumilast versus 10 mg Montelukast. A 24 weeks double-blind study in patients with Asthma. The PRIME-study.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006411
title: A comparison of treatment with 250 ?g roflumilast versus 500 ?g roflumilast versus placebo over 24 weeks in patients with chronic obstructive pulmonary disease (COPD).

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006412
title: A 24 Week, Placebo-Controlled, Randomized, Parallel Group Study Comparing Roflumilast 500 Mcg Daily vs Placebo on Pulmonary Function and Respiratory Symptoms in Patients With Chronic Obstructive Pulmonary Disease (COPD).

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006413
title: Effect of 500 ?g roflumilast on exercise tolerance and respiratory reserve in patients with chronic obstructive pulmonary disease. A 12 weeks double blind study  with roflumilast once daily versus placebo. The INSPIRE Study


description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006414
title: An Open, Randomised, Multi-centre Trial Comparing the Efficacy and Tolerability of 125 mg and 250 mg of FASLODEXTM (Long-acting ICI 182,780) with 1 mg ARIMIDEXTM (Anastrozole) in Postmenopausal Women with Advanced Breast Cancer


description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006901
title: A Phase I/II Trial of ZD1839 (Iressa) Given Concurrently With Cisplatin and Radiotherapy in Patients With Locally Advanced Head and Neck Cancer

description: To determine the safety and tolerability of gefitinib in combination with cisplatin and radiation (3D-CRT or IMRT) in patients with locally advanced head and neck cancer.
DOI: 10.25934/00006908
title: A Long-term Study of APTA-2217 in Patients With Chronic Obstructive Pulmonary Disease

description: The aim of this long-term study is to investigate the effect of roflumilast (APTA-2217) on the long-term safety in patients with chronic obstructive pulmonary disease (COPD) who completed the 24-week evaluation of study APTA-2217-06. Roflumilast will be administered orally once daily. The present study consists of a 28 weeks treatment period, and is an extension of the 24-week study APTA-2217-06 (registered study). The study will provide further long-term safety and efficacy data of roflumilast.
DOI: 10.25934/00006897
title: A Phase II Trial to Assess the Efficacy of IRESSA™ (Gefitinib) 500 mg/Day in Patients With Breast Cancer Who Have Failed Tamoxifen or Have an Oestrogen Receptor Negative Tumour and Would be Considered for Systemic Therapy

description: This is a phase II trial to assess whether IRESSA™ (gefitinib) has anti-tumour efficacy in patients with breast cancer. The trial proposes to enter 27 patients who have acquired resistance to tamoxifen and 27 patients with ER negative tumours. However for each of these two types of patients recruitment will stop after 14 patients have been entered in order to confirm that IRESSA™ (gefitinib)has anti-tumour efficacy. If no patient out of 14 in a group has shown clinical benefit (ie an objective response (CR or PR) or stable disease (SD) for at least 24 weeks) then a clinical benefit rate of >20% can be ruled out with >95% certainty. If one or more of the objective response or stable disease (> 24 weeks) has been seen in the first 14 patients recruited in a group then recruitment to that group will recommence to a total of 27 patients. If 14 patients are entered into an arm but not all 14 patients are available for final analysis and the toxicity/safety and tolerability profile of the therapy is acceptable and documented and a clinical benefit is seen in the patients, enrolment of additional patients beyond the initial 14 may be made based on overall clinical assessment.
DOI: 10.25934/00006912
title: Investigation of Safety and Efficacy of Budesonide Inhalation Suspension in the Long-Term Use in Japanese Children With Bronchial Asthma (Open Long-Term Extension Study Following Study SD-004-0765

description: This study is as an extension study of SD-004-0765, to assess the safety profile of long-term use of budesonide inhalation suspension in Japanese young children with bronchial asthma. Children completing study SD-004-0765 continued administration of budesonide inhalation suspension as judged by the investigator; the dose is adjusted as appropriate within the range of 0.25 to 1.0 mg per day administered once or twice daily, according to the symptoms.
DOI: 10.25934/00006913
title: A Phase II, Randomised, Double-Blind, Placebocontrolled Study To Investigate The Effects Of ZD1839 (IRESSA™) On Cell Proliferation In Oestrogen And Progesterone Receptor Negative Breast Cancer Prior To Surgery

description: This is a Phase II, randomised, double-blind, placebo-controlled study. Subjects with histologically-confirmed oestrogen receptor negative (ER-), progesterone receptor negative (PgR-) primary breast cancer breast cancer will be randomly assigned in a 2:1 ratio to receive ZD1839 250 mg once daily or matching placebo for a total period of 5 weeks. Surgical intervention will take place after 4 weeks (on Day 29) and treatment will continue for 1 week after surgery.
DOI: 10.25934/00006911
title: A Placebo-controlled Comparison of the Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Children and Adolescents.

description: A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently approved Pulmicort Turbuhaler with a new version of the inhaler, in children and adolescents who have asthma. In addition the study evaluated the functionality of the new inhaler at the end of its intended life.
DOI: 10.25934/00006997
title: A randomised, double-blind, multicentre phase II trial to evaluate the biological effects, safety and pharmacokinetics of single agent ZD1839 (IressaTM) and ZD1839 in combination with anastrozole (Arimidex) in patients with primary breast cancer

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006895
title: Phase II Study of Iressa in Relapsed and Refractory Small Cell Lung Cancer

description: The purpose of this study is to determine the disease control rate at trial closure and after the first stage of the study in patients with relapsed or refractory SCLC and measurable disease treated with gefitinib
DOI: 10.25934/00006900
title: A Multicentre, Randomised, Double-Blind, Non-Comparative Phase II Trial Of ZD1839 (Iressa™) And Placebo In Combination With Chemotherapy With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer

description: This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast cancer.
DOI: 10.25934/00006910
title: A Placebo-controlled Comparison of the Efficacy and Safety of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Adults Currently Treated With Inhaled Steroids.

description: A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently approved Pulmicort Turbuhaler with a new version of the inhaler, in adult patients who have asthma and are currently being treated with inhaled steroids. In addition the study evaluated the functionality of the new inhaler at the end of its intended life.
DOI: 10.25934/00007021
title: The FLASH Study: A Randomized, Controlled Study of Roflumilast 250 Mcg and 500 Mcg Versus Placebo in Patients With Asthma.

description: Vivli is an independent, non-profit organization that has developed a global data-sharing and analytics platform to serve all elements of the international research community. Our mission is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the creation and implementation of a sustainable global data-sharing enterprise. The Vivli platform includes an independent data repository, in-depth search engine and a cloud-based, secure analytics platform.
DOI: 10.25934/00006909
title: Multicenter Phase II Trial of Gefitinib (Iressa™) First Line Therapy Followed by Chemotherapy in Advanced Non-Small Cell Lung Cancer (NSCLC)

description: RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving gefitinib as first-line therapy followed by gemcitabine and cisplatin after disease progression may be an effective treatment for non-small cell lung cancer. PURPOSE: This phase II trial is studying how well gefitinib works as first-line therapy followed by gemcitabine and cisplatin in treating patients with stage III or stage IV non-small cell lung cancer.
DOI: 10.6084/m9.figshare.17088980.v1
title: Priming measures for overt and covert naming participants in Gotts, Milleville, & Martin (2021) Communications Biology.

description: Raw priming, proportional priming, effect size priming, and base response time (RT) for the 32 overt naming and 28 covert naming participants in Gotts, Milleville, & Martin (2021) Communications Biology. Priming effects for the covert naming participants were measured in the post-fMRI overt naming session.
DOI: 10.6084/m9.figshare.17088980
title: Priming measures for overt and covert naming participants in Gotts, Milleville, & Martin (2021) Communications Biology.

description: Raw priming, proportional priming, effect size priming, and base response time (RT) for the 32 overt naming and 28 covert naming participants in Gotts, Milleville, & Martin (2021) Communications Biology. Priming effects for the covert naming participants were measured in the post-fMRI overt naming session.
DOI: 10.5281/zenodo.5724019
title: Data set - Monitoring light pollution with an unmanned aerial vehicle

description: Dataset used in the study Monitoring light pollution with an unmanned aerial vehicle. A digital camera and a sky quality meter mounted on a UAV have been used to study the relationship between indices computed on night images and night ground brightness (NGB) measured by an optical device pointed downward towards the ground. Both measurements were taken contemporarily during flights at 70 meter and 100 meters altitude, and also varying exposure time.
DOI: 10.5281/zenodo.5724018
title: Data set - Monitoring light pollution with an unmanned aerial vehicle

description: Dataset used in the study Monitoring light pollution with an unmanned aerial vehicle. A digital camera and a sky quality meter mounted on a UAV have been used to study the relationship between indices computed on night images and night ground brightness (NGB) measured by an optical device pointed downward towards the ground. Both measurements were taken contemporarily during flights at 70 meter and 100 meters altitude, and also varying exposure time.
DOI: 10.5281/zenodo.5733173
title: Bioactive fatty-acid derivated ovalicin from Pseudallescheria boydii

description: Original data for the mMolecular network with t-SNE representation of crude extracts of <em>P. boydii</em>. SNB-CN71, -CN73, -CN81 and -CN85
description: LC-MS/MS data set
DOI: 10.5281/zenodo.5733172
title: Bioactive fatty-acid derivated ovalicin from Pseudallescheria boydii

description: Original data for the mMolecular network with t-SNE representation of crude extracts of <em>P. boydii</em>. SNB-CN71, -CN73, -CN81 and -CN85
description: LC-MS/MS data set
DOI: 10.6084/m9.figshare.17089004
title: Questionnaire

description: questionnaire
DOI: 10.6084/m9.figshare.17089004.v1
title: Questionnaire

description: questionnaire
DOI: 10.25934/00002903
title: A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension

description: This is a multicenter study conducted in 3 parts. Part A is a double-blind placebo-controlled parallel-group period, and Part B and C are open-label extension periods. The primary objective of the double-blind study (Part A) is to assess the effect of Prolonged-Release Fampridine treatment on walking speed as measured by the T25FW (timed 25 foot walk) in Japanese participants with Multiple Sclerosis. The secondary objective of the double-blind portion of the study is to evaluate the safety and tolerability of prolonged-release Fampridine in this study population. The primary objective of the open-label extension study (Part B) is to evaluate the long-term safety profile of prolonged-release Fampridine. The primary objective of the additional open-label extension (Part C) is to provide participants who complete the study with continued access to prolonged-release fampridine until marketed drug can be used at the applicable site or until sponsor decision to discontinue the study.
DOI: 10.5281/zenodo.5732905
title: MRSI

description: A Multimodal Proximity Remote Sensing Dataset for Environment Perception in Rail Transit
DOI: 10.5281/zenodo.5732904
title: MRSI

description: A Multimodal Proximity Remote Sensing Dataset for Environment Perception in Rail Transit
DOI: 10.6084/m9.figshare.17088857
title: Datasets for the study: "Sensorimotor integration within the primary motor cortex by selective nerve fascicle stimulation"

description: Datasets for the study: "Sensorimotor integration within the primary motor cortex by selective nerve fascicle stimulation" (see article for details).<br>
DOI: 10.6084/m9.figshare.17088857.v2
title: Datasets for the study: "Sensorimotor integration within the primary motor cortex by selective nerve fascicle stimulation"

description: Datasets for the study: "Sensorimotor integration within the primary motor cortex by selective nerve fascicle stimulation" (see article for details).<br>
DOI: 10.6084/m9.figshare.17088857.v1
title: Datasets for the study: "Sensorimotor integration within the primary motor cortex by selective nerve fascicle stimulation"

description: Datasets for the study: "Sensorimotor integration within the primary motor cortex by selective nerve fascicle stimulation" (see article for details).<br>
DOI: 10.5519/qd.7w7fd3mq
title: Query on the Natural History Museum Data Portal (data.nhm.ac.uk) (4970696 records)
DOI: 10.25934/00003391
title: An Open-label, Non-randomized, Single-arm Study, to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma High Density Lipoproteins Concentration in HIV+ Subjects Treated With VIRAMUNE® Tablets

description: 1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated. In addition, the activity of the key enzymes related to HDL metabolism were assessed. [ Designated as safety issue: No ]   2. In order to determine the relevance of the HDL increase in decreasing cardiovascular risk in HIV-positive subjects we evaluated endothelial function (FMD) as a surrogate marker for cardiovascular disease in patients. [ Designated as safety issue: No ]